Mobile Site ›

Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation


Subscribe

Receive notification when new Hot Topics are published:

Clinical Utility

Slide 14

January 2011

This then can help distinguish autoimmune GI dysmotility from chemotherapy side effects. Finally, a rising antibody titer in a previously seropositive patient can suggest cancer recurrence.

Clinical Utility

 


Jump to section:


Key